Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S.

Corrine E. Munoz-Plaza, Shiela Strauss, Janetta Astone-Twerell, Don Des Jarlais, Marya Gwadz, Holly Hagan, Andrew Osborne, Andrew Rosenblum

Research output: Contribution to journalArticle

Abstract

Individuals with a history of injecting drugs are at the highest risk of becoming infected with the hepatitis C virus (HCV), with studies of patients in methadone maintenance treatment programmes (MMTPs) reporting that 60-90 percent of intravenous drug users (IDUs) have the virus. Fortunately, HCV therapy has been shown to be effective in 42-82 percent of all patients with chronic HCV infection, including IDUs. While the decision to start HCV therapy requires significant consideration, little research exists that explores the attitudes of drug users toward HCV therapy. Therefore, this paper examines how drug users perceive the treatment, as well as the processes by which HCV-positive individuals examined the advantages and disadvantages of starting the HCV medications. Interviews were conducted with 164 patients from 14 drug treatment programmes throughout the United States, and both uninfected and HCV-positive drug users described a pipeline of communication among their peers that conveys largely negative messages about the medications that are available to treat HCV. Although many of the HCV-positive individuals said that these messages heightened their anxiety about the side effects and difficulties of treatment, some patients said that their peers helped them to consider, initiate HCV treatment or both. Gaining a better understanding of drug users' perceptions of HCV treatment is important, because so many of them, particularly IDUs, are already infected with HCV and may benefit from support in addressing their HCV treatment needs. In addition, currently uninfected drug users will likely remain at high risk for contracting HCV and may need to make decisions about whether or not to start the HCV medical regimen in the future.

Original languageEnglish (US)
Pages (from-to)71-78
Number of pages8
JournalInternational Journal of Drug Policy
Volume19
Issue number1
DOIs
StatePublished - Feb 2008

Fingerprint

Hepatitis C
Drug Users
Hepacivirus
contagious disease
drug
Therapeutics
medication
Methadone
Chronic Hepatitis C
Virus Diseases
Pharmaceutical Preparations

Keywords

  • Drug treatment programmes
  • Hepatitis C
  • Medical treatment
  • Substance abuse

ASJC Scopus subject areas

  • Medicine(all)
  • Health Policy
  • Health(social science)

Cite this

Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S. / Munoz-Plaza, Corrine E.; Strauss, Shiela; Astone-Twerell, Janetta; Des Jarlais, Don; Gwadz, Marya; Hagan, Holly; Osborne, Andrew; Rosenblum, Andrew.

In: International Journal of Drug Policy, Vol. 19, No. 1, 02.2008, p. 71-78.

Research output: Contribution to journalArticle

Munoz-Plaza, Corrine E. ; Strauss, Shiela ; Astone-Twerell, Janetta ; Des Jarlais, Don ; Gwadz, Marya ; Hagan, Holly ; Osborne, Andrew ; Rosenblum, Andrew. / Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S. In: International Journal of Drug Policy. 2008 ; Vol. 19, No. 1. pp. 71-78.
@article{5f65984f25124e79b8635b1ad043f579,
title = "Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S.",
abstract = "Individuals with a history of injecting drugs are at the highest risk of becoming infected with the hepatitis C virus (HCV), with studies of patients in methadone maintenance treatment programmes (MMTPs) reporting that 60-90 percent of intravenous drug users (IDUs) have the virus. Fortunately, HCV therapy has been shown to be effective in 42-82 percent of all patients with chronic HCV infection, including IDUs. While the decision to start HCV therapy requires significant consideration, little research exists that explores the attitudes of drug users toward HCV therapy. Therefore, this paper examines how drug users perceive the treatment, as well as the processes by which HCV-positive individuals examined the advantages and disadvantages of starting the HCV medications. Interviews were conducted with 164 patients from 14 drug treatment programmes throughout the United States, and both uninfected and HCV-positive drug users described a pipeline of communication among their peers that conveys largely negative messages about the medications that are available to treat HCV. Although many of the HCV-positive individuals said that these messages heightened their anxiety about the side effects and difficulties of treatment, some patients said that their peers helped them to consider, initiate HCV treatment or both. Gaining a better understanding of drug users' perceptions of HCV treatment is important, because so many of them, particularly IDUs, are already infected with HCV and may benefit from support in addressing their HCV treatment needs. In addition, currently uninfected drug users will likely remain at high risk for contracting HCV and may need to make decisions about whether or not to start the HCV medical regimen in the future.",
keywords = "Drug treatment programmes, Hepatitis C, Medical treatment, Substance abuse",
author = "Munoz-Plaza, {Corrine E.} and Shiela Strauss and Janetta Astone-Twerell and {Des Jarlais}, Don and Marya Gwadz and Holly Hagan and Andrew Osborne and Andrew Rosenblum",
year = "2008",
month = "2",
doi = "10.1016/j.drugpo.2007.02.003",
language = "English (US)",
volume = "19",
pages = "71--78",
journal = "International Journal of Drug Policy",
issn = "0955-3959",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S.

AU - Munoz-Plaza, Corrine E.

AU - Strauss, Shiela

AU - Astone-Twerell, Janetta

AU - Des Jarlais, Don

AU - Gwadz, Marya

AU - Hagan, Holly

AU - Osborne, Andrew

AU - Rosenblum, Andrew

PY - 2008/2

Y1 - 2008/2

N2 - Individuals with a history of injecting drugs are at the highest risk of becoming infected with the hepatitis C virus (HCV), with studies of patients in methadone maintenance treatment programmes (MMTPs) reporting that 60-90 percent of intravenous drug users (IDUs) have the virus. Fortunately, HCV therapy has been shown to be effective in 42-82 percent of all patients with chronic HCV infection, including IDUs. While the decision to start HCV therapy requires significant consideration, little research exists that explores the attitudes of drug users toward HCV therapy. Therefore, this paper examines how drug users perceive the treatment, as well as the processes by which HCV-positive individuals examined the advantages and disadvantages of starting the HCV medications. Interviews were conducted with 164 patients from 14 drug treatment programmes throughout the United States, and both uninfected and HCV-positive drug users described a pipeline of communication among their peers that conveys largely negative messages about the medications that are available to treat HCV. Although many of the HCV-positive individuals said that these messages heightened their anxiety about the side effects and difficulties of treatment, some patients said that their peers helped them to consider, initiate HCV treatment or both. Gaining a better understanding of drug users' perceptions of HCV treatment is important, because so many of them, particularly IDUs, are already infected with HCV and may benefit from support in addressing their HCV treatment needs. In addition, currently uninfected drug users will likely remain at high risk for contracting HCV and may need to make decisions about whether or not to start the HCV medical regimen in the future.

AB - Individuals with a history of injecting drugs are at the highest risk of becoming infected with the hepatitis C virus (HCV), with studies of patients in methadone maintenance treatment programmes (MMTPs) reporting that 60-90 percent of intravenous drug users (IDUs) have the virus. Fortunately, HCV therapy has been shown to be effective in 42-82 percent of all patients with chronic HCV infection, including IDUs. While the decision to start HCV therapy requires significant consideration, little research exists that explores the attitudes of drug users toward HCV therapy. Therefore, this paper examines how drug users perceive the treatment, as well as the processes by which HCV-positive individuals examined the advantages and disadvantages of starting the HCV medications. Interviews were conducted with 164 patients from 14 drug treatment programmes throughout the United States, and both uninfected and HCV-positive drug users described a pipeline of communication among their peers that conveys largely negative messages about the medications that are available to treat HCV. Although many of the HCV-positive individuals said that these messages heightened their anxiety about the side effects and difficulties of treatment, some patients said that their peers helped them to consider, initiate HCV treatment or both. Gaining a better understanding of drug users' perceptions of HCV treatment is important, because so many of them, particularly IDUs, are already infected with HCV and may benefit from support in addressing their HCV treatment needs. In addition, currently uninfected drug users will likely remain at high risk for contracting HCV and may need to make decisions about whether or not to start the HCV medical regimen in the future.

KW - Drug treatment programmes

KW - Hepatitis C

KW - Medical treatment

KW - Substance abuse

UR - http://www.scopus.com/inward/record.url?scp=38849099640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849099640&partnerID=8YFLogxK

U2 - 10.1016/j.drugpo.2007.02.003

DO - 10.1016/j.drugpo.2007.02.003

M3 - Article

C2 - 18312822

AN - SCOPUS:38849099640

VL - 19

SP - 71

EP - 78

JO - International Journal of Drug Policy

JF - International Journal of Drug Policy

SN - 0955-3959

IS - 1

ER -